OTCMKTS:PMCBD PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis $1.03 -0.04 (-3.74%) As of 05/29/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About PharmaCyte Biotech Stock (OTCMKTS:PMCBD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PharmaCyte Biotech alerts:Sign Up Key Stats Today's Range$1.01▼$1.0550-Day Range$1.01▼$1.5652-Week Range$5.56▼$55.50Volume1,994 shsAverage Volume8,831 shsMarket Capitalization$1.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.Read More… Receive PMCBD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCBD Stock News HeadlinesPharmaCyte Biotech (PMCB) Earnings Dates & ReportsSeptember 27, 2024 | investing.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024March 19, 2024 | investorplace.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 30, 2025 | Porter & Company (Ad)PharmaCyte Biotech Inc (PMCB)February 22, 2024 | investing.comExploring beauty’s biotech frontierOctober 27, 2023 | ft.comPMCB PharmaCyte Biotech, Inc.May 26, 2023 | seekingalpha.comPharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender OfferMay 11, 2023 | marketwatch.comBaltimore Biotech NewsApril 28, 2023 | bizjournals.comSee More Headlines PMCBD Stock Analysis - Frequently Asked Questions How have PMCBD shares performed this year? PharmaCyte Biotech's stock was trading at $1.55 at the start of the year. Since then, PMCBD shares have decreased by 33.5% and is now trading at $1.03. View the best growth stocks for 2025 here. How do I buy shares of PharmaCyte Biotech? Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:PMCBD CIKN/A Webwww.pharmacyte.com Phone(917) 595-2850FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.09% Return on Assets-43.39% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,671,000Free FloatN/AMarket Cap$1.72 million OptionableNot Optionable Beta0.27 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (OTCMKTS:PMCBD) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
